Figure. Adjusted Vaccine Effectiveness Associated With BNT162b2 Against Emergency Department and Urgent Care Encounters (Without Subsequent Hospitalization) for Delta- or Omicron-Related Acute Respiratory Illness.

Vaccine effectiveness (dots) and 95% CIs (whiskers) are based on results from multivariable logistic regression analysis comparing adolescents aged 12 to 17 years who received the 2-dose primary or a third dose of BNT162b2 compared with individuals who were unvaccinated, adjusted for age, sex, race and ethnicity, body mass index, prior positive results on a SARS-CoV-2 test, pediatric comorbidity index, and admission date. Sample size was insufficient to estimate effectiveness of 3 doses of BNT162b2 against the Delta variant.